57415-44-8

Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT)[1][2][3].

Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na+ current (INa) and the rapid component of the delayed rectifier K+ current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias[1][2][3].

[1]. Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8.[2]. Aliot E, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011 Feb;13(2):161-73.[3]. Allan LD, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J. 1991 Jan;65(1):46-8.